Niraparib tosylate monohydrate

Drug Overview

Niraparib tosylate monohydrate (brand name Zejula) is an orally bioavailable, small-molecule inhibitor of the enzymes poly(ADP-ribose) polymerase (PARP) types 1 and 2. It is a potent antineoplastic agent used primarily as a maintenance therapy to prevent the recurrence of specific gynecological and urological cancers.

In the clinical landscape of March 2026, niraparib is recognized as a cornerstone of “synthetic lethality” in oncology. It is particularly effective in treating tumors that have a “broken” DNA repair system, such as those with BRCA1/2 mutations or Homologous Recombination Deficiency (HRD). By further blocking the remaining repair pathways, niraparib forces these cancer cells to accumulate lethal amounts of DNA damage, leading to cell death while sparing most healthy, repair-competent cells.

• Generic Name: Niraparib tosylate monohydrate.
• Brand Name: Zejula.
• Drug Class: PARP-1/2 Inhibitor.
• Mechanism: Inhibition of DNA repair (PARylation) and “PARP trapping” on damaged DNA.
• Route of Administration: Oral (Capsule/Tablet).
• FDA Approval Status: FDA-approved (Initial approval: March 2017).

What Is It and How Does It Work? (Mechanism of Action)

Niraparib utilizes a specialized biological strategy to target cancer cells that are already genetically vulnerable.

1. The Principle of Synthetic Lethality

Healthy cells have multiple “backup systems” to fix DNA damage. Cancer cells with BRCA mutations have lost a major system called Homologous Recombination (HR).

• PARP Inhibition: Niraparib blocks the PARP enzymes, which are responsible for fixing single-strand DNA breaks.
• Double-Strand Breaks: In a BRCA-mutated cell, these un-fixed single-strand breaks turn into double-strand breaks during cell division.
• Cell Death: Because the cell has no backup system (due to the BRCA mutation), the damage becomes catastrophic, and the cell dies.

2. PARP Trapping

Beyond just “turning off” the enzyme, niraparib acts like a “physical clamp.” It traps the PARP protein onto the damaged DNA strand. This trapped complex acts as a roadblock that interferes with DNA replication, causing the replication fork to collapse—a much more potent way of killing cancer cells than simple enzyme inhibition alone.

3. Broad Applicability (The HRD Niche)

While early PARP inhibitors were only for BRCA-mutated patients, niraparib has shown efficacy in a broader population. This includes patients with HRD-positive tumors (which have repair defects similar to BRCA) and even some patients with “wild-type” (normal) BRCA, though the benefit is most pronounced in the mutation-positive groups.

FDA Approved Clinical Indications (2026)

As of March 2026, niraparib is approved for several high-impact oncology indications:

• First-line Maintenance (Ovarian Cancer): For adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had a complete or partial response to first-line platinum-based chemotherapy.
• Recurrent Maintenance (Ovarian Cancer): For adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy (regardless of BRCA status).
• Advanced Treatment (Ovarian Cancer): For patients who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with HRD-positive status.
• Prostate Cancer (Akeega): In December 2025, the FDA approved a fixed-dose combination of niraparib and abiraterone acetate (marketed as Akeega) with prednisone for adult patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).

Dosage and Administration Protocols

Niraparib is known for its “Individualized Starting Dose” ( ISD ), which was introduced to reduce the risk of blood-related side effects.

Clinical Efficacy and Research Results (2024–2026)

Recent data has highlighted the “long-term” durability of niraparib treatment:

• PRIMA Trial (5-Year Update): Data published in late 2024 and early 2025 showed that patients in the HRD-positive group who received niraparib maintenance were significantly more likely to be alive and progression-free at 5 years compared to those on placebo (35% vs. 16%).
• AMPLITUDE Trial (Prostate): This pivotal trial led to the 2025 approval in prostate cancer, demonstrating that adding niraparib to standard hormonal therapy (abiraterone) reduced the risk of radiographic progression by 54% in BRCA2-mutated patients.
• Blood-Brain Barrier: Recent pharmacological studies have confirmed that niraparib has better CNS (central nervous system) penetration than some other PARP inhibitors, leading to ongoing research in brain metastases.

Safety Profile and Side Effects

The primary side effects of niraparib are hematologic (related to blood counts) and cardiovascular.

Common Side Effects (>25%):

• Hematologic: Thrombocytopenia (low platelets), anemia (low red cells), and neutropenia (low white cells).
• Gastrointestinal: Nausea, constipation, vomiting, and decreased appetite.
• Systemic: Fatigue, headache, and insomnia.

Serious Risks:

• MDS/AML: A very rare but serious risk (<1.5%) of developing secondary bone marrow cancers like Myelodysplastic Syndrome or Acute Myeloid Leukemia.
• Hypertension: High blood pressure and increased heart rate are common; blood pressure must be monitored weekly for the first two months.
• Liver Toxicity: Rare elevations in liver enzymes.
• Posterior Reversible Encephalopathy Syndrome (PRES): A rare neurological disorder characterized by seizures, headache, and confusion.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, niraparib is being used to study “Genomic Stability.” Researchers are investigating how PARP inhibition affects the repair of “telomeres” (the protective caps on chromosomes) in hematopoietic stem cells. In 2026, there is also intense focus on “Immune Synergism.” Scientists are exploring if the DNA damage caused by niraparib can “prime” the tumor to be more visible to PD-1 inhibitors by activating the cGAS/STING pathway, which alerts the immune system to the presence of cytosolic DNA.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Weight and Platelets: Baseline measurements are mandatory to determine the  ISD  (200 mg vs. 300 mg).
• Blood Pressure: Establishment of a baseline blood pressure.

“Do’s and Don’ts” List:

• DO have your blood counts checked weekly for the first month; most dose adjustments for low platelets happen early in treatment.
• DO monitor your blood pressure at home, especially in the first two months.
• DON’T swallow the capsule if it is broken or open; it must be swallowed whole.
• DON’T ignore signs of infection (fever) or unusual bruising, as these could be signs of serious bone marrow suppression.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Niraparib (Zejula) is a potent targeted therapy that requires specialized monitoring. Always consult with your oncologist regarding your specific diagnosis, genetic testing (BRCA/HRD) status, and any potential side effects.